A Phase 3 interventional study of Tirzepatide and Placebo in Obesity and Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by Eli Lilly and Company. Completed at 146 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 10th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 8th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 731 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 27th largest by enrollment of the 117 interventional ones that give a count, is one of 8 that started in 2021, is one of 51 in phase 3, and was the 9th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
The study will continue until approximately 52 weeks after the last participant is randomized. The maximum duration of an individual's participation is estimated to be \~120 weeks and will depend on duration of study enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or maximum tolerated dose (MTD) tolerated by the participant (5 mg QW or 10 mg QW).
Drug: Tirzepatide
Participants received placebo administered SC QW.
Other: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
The KCCQ is a 23-item, participant self-administered questionnaire that assesses impacts of heart failure "over the past 2 weeks" on the following 7 domains: * Physical Limitation (6) * Symptom Stability (1) * Symptom Frequency (4) * Symptom Burden (3) * Self-Efficacy (2) * Quality of Life (3) * Social Limitation (4) Each of the 23 individual items are answered on Likert scales of varying lengths (5, 6, or 7-point scales). KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are obtained by averaging the associated individual items and transforming the score to a 0 to 100 range. Higher scores indicate better health status. Least Square (LS) mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables .
Time frame: Baseline, Week 52
First Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes
Clinical Endpoint Committe confirmed Occurrences of CV outcomes were reported here. HF outcomes consisted of cardiovascular death and HF events. The HF events were defined as worsening clinical symptoms or signs related to HF, which are meaningful to the participant and require intensification of treatment characterized by 1 or more of the following: * hospitalization for heart failure regardless of duration or treatment received * use of intravenous drug, usually an intravenous diuretic, but may include intravenous vasodilators or positive inotropic drugs, or * augmentation or increase in oral diuretic therapy.
Time frame: Baseline Up To 160 weeks
Change From Baseline in Exercise Capacity as Measured by 6-Minute Walk Distance (6MWD)
Participants performed an exercise capacity assessment using the 6-Minute Walk Test (6MWT) and the distance covered (6MWD) was assessed in meters. The 6MWT was performed indoors on a straight, flat, hard surface that is at least 30 meters in length. The greater distance walked meant better physical capacity. LS Mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Percent Change From Baseline in Body Weight
Percent change in bodyweight was reported. LS mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Percent change from baseline in hsCRP was reported. LS Mean was determined using ANCOVA model with log (actual measurement/baseline) = log (baseline) + HF decompensation within 12 months of screening + T2DM status + baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Win Percentage of the Hierarchical Composite Endpoint
Hierarchical Composite Endpoint included time to all-cause death, number of HF events, time to first HF events, KCCQ-CSS, 6MWD. The winner was determined in each pair-wise comparison in the following order: * A delayed first occurrence of all-cause death * If the pair cannot be differentiated based on death, winner has fewer HF events * If the pair cannot be differentiated by number of HF events, winner has delayed time to occurrence of first HF event * If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in 6MWD * If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in KCCQ-CSS * Otherwise the pair will be recorded as tied. Reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.
Time frame: Baseline Up To 160 Weeks
Percentage of Participants With New York Heart Association (NYHA) Class Change
Percentage of participants with NYHA class change at Week 52 was reported.
Time frame: Week 52
Number of Participants With Time to All-Cause Death
All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.
Time frame: Baseline Up To 160 Weeks
Number of Participants With Time to First Occurrence of HF Events
Number of participants with time to first occurrence of HF events are reported.
Time frame: Baseline Up To 160 Weeks
Number of HF Events and All-Cause Death
Number of HF events and all-cause death are reported.
Time frame: Baseline Up To 160 Weeks.
Number of Recurrent HF Events
Number of recurrent HF events were reported.
Time frame: Baseline Up To 160 Weeks.
| Milestone | Tirzepatide - MTD | Placebo |
|---|---|---|
| Started | 364 | 367 |
| Received at least one dose of study drug | 364 | 367 |
| Completed | 332 | 331 |
| Not completed | 32 | 36 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 19 | 15 |
| Withdrew: Lost to follow-up | 3 | 6 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 14 |
The KCCQ is a 23-item, participant self-administered questionnaire that assesses impacts of heart failure "over the past 2 weeks" on the following 7 domains: * Physical Limitation (6) * Symptom Stability (1) * Symptom Frequency (4) * Symptom Burden (3) * Self-Efficacy (2) * Quality of Life (3) * Social Limitation (4) Each of the 23 individual items are answered on Likert scales of varying lengths (5, 6, or 7-point scales). KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are obtained by averaging the associated individual items and transforming the score to a 0 to 100 range. Higher scores indicate better health status. Least Square (LS) mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables .
| Score on a scale | Tirzepatide - MTD | Placebo |
|---|---|---|
| Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) | 19.51 ± 1.24 | 12.68 ± 1.25 |
Clinical Endpoint Committe confirmed Occurrences of CV outcomes were reported here. HF outcomes consisted of cardiovascular death and HF events. The HF events were defined as worsening clinical symptoms or signs related to HF, which are meaningful to the participant and require intensification of treatment characterized by 1 or more of the following: * hospitalization for heart failure regardless of duration or treatment received * use of intravenous drug, usually an intravenous diuretic, but may include intravenous vasodilators or positive inotropic drugs, or * augmentation or increase in oral diuretic therapy.
| Number of events | Tirzepatide - MTD | Placebo |
|---|---|---|
| First Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes | 36 | 56 |
Participants performed an exercise capacity assessment using the 6-Minute Walk Test (6MWT) and the distance covered (6MWD) was assessed in meters. The 6MWT was performed indoors on a straight, flat, hard surface that is at least 30 meters in length. The greater distance walked meant better physical capacity. LS Mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.
| meters | Tirzepatide - MTD | Placebo |
|---|---|---|
| Change From Baseline in Exercise Capacity as Measured by 6-Minute Walk Distance (6MWD) | 26.04 ± 3.81 | 10.10 ± 3.94 |
Percent change in bodyweight was reported. LS mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.
| Percent change | Tirzepatide - MTD | Placebo |
|---|---|---|
| Percent Change From Baseline in Body Weight | -13.85 ± 0.43 | -2.24 ± 0.46 |
Percent change from baseline in hsCRP was reported. LS Mean was determined using ANCOVA model with log (actual measurement/baseline) = log (baseline) + HF decompensation within 12 months of screening + T2DM status + baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables.
| Percent change | Tirzepatide - MTD | Placebo |
|---|---|---|
| Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) | -38.76 ± 4.47 | -5.88 ± 5.25 |
Hierarchical Composite Endpoint included time to all-cause death, number of HF events, time to first HF events, KCCQ-CSS, 6MWD. The winner was determined in each pair-wise comparison in the following order: * A delayed first occurrence of all-cause death * If the pair cannot be differentiated based on death, winner has fewer HF events * If the pair cannot be differentiated by number of HF events, winner has delayed time to occurrence of first HF event * If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in 6MWD * If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in KCCQ-CSS * Otherwise the pair will be recorded as tied. Reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.
| Win percentage | Tirzepatide - MTD | Placebo |
|---|---|---|
| Win Percentage of the Hierarchical Composite Endpoint | 57.90 | 35.43 |
Percentage of participants with NYHA class change at Week 52 was reported.
| Percentage of participants | Tirzepatide - MTD | Placebo |
|---|---|---|
| Percentage of Participants With New York Heart Association (NYHA) Class Change | 33.27 | 20.39 |
All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.
| Participants | Tirzepatide - MTD | Placebo |
|---|---|---|
| Number of Participants With Time to All-Cause Death | 19 | 15 |
Number of participants with time to first occurrence of HF events are reported.
| Participants | Tirzepatide - MTD | Placebo |
|---|---|---|
| Number of Participants With Time to First Occurrence of HF Events | 29 | 52 |
Number of HF events and all-cause death are reported.
| Events | Tirzepatide - MTD | Placebo |
|---|---|---|
| Number of HF Events and All-Cause Death | 61 | 82 |
Number of recurrent HF events were reported.
| Events | Tirzepatide - MTD | Placebo |
|---|---|---|
| Number of Recurrent HF Events | 44 | 68 |
Collected over Baseline Up To 162 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirzepatide - MTD | 19/364 (5.2%) | 96/364 (26.4%) | 221/364 (60.7%) |
| Placebo | 15/367 (4.1%) | 94/367 (25.6%) | 137/367 (37.3%) |
| Event | Tirzepatide - MTD | Placebo |
|---|---|---|
| Cardiac failureCardiac disorders | 12/364 | 18/367 |
| Cardiac failure congestiveCardiac disorders | 3/364 | 12/367 |
| Atrial fibrillationCardiac disorders | 7/364 | 3/367 |
| Acute myocardial infarctionCardiac disorders | 6/364 | 2/367 |
| Cholecystitis acuteHepatobiliary disorders | 6/364 | 4/367 |
| CellulitisInfections and infestations | 0/364 | 6/367 |
| PneumoniaInfections and infestations | 5/364 | 6/367 |
| Urinary tract infectionInfections and infestations | 5/364 | 1/367 |
| Acute kidney injuryRenal and urinary disorders | 5/364 | 3/367 |
| AnaemiaBlood and lymphatic system disorders | 1/364 | 5/367 |
| Event | Tirzepatide - MTD | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 65/364 | 23/367 |
| NauseaGastrointestinal disorders | 62/364 | 23/367 |
| ConstipationGastrointestinal disorders | 54/364 | 22/367 |
| Covid-19Infections and infestations | 33/364 | 41/367 |
| VomitingGastrointestinal disorders | 38/364 | 7/367 |
| Decreased appetiteMetabolism and nutrition disorders | 38/364 | 6/367 |
| DizzinessNervous system disorders | 34/364 | 18/367 |
| Urinary tract infectionInfections and infestations | 31/364 | 22/367 |
| DyspepsiaGastrointestinal disorders | 23/364 | 8/367 |
| HypotensionVascular disorders | 22/364 | 10/367 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Tirzepatide - MTD | Placebo | Total |
|---|---|---|---|
| Mean | 65.50 ± 10.53 | 65.00 ± 10.87 | 65.20 ± 10.70 |
| Sex: Female, Male(Participants) | Tirzepatide - MTD | Placebo | Total |
|---|---|---|---|
| Female | 200 | 193 | 393 |
| Male | 164 | 174 | 338 |
| Ethnicity (NIH/OMB)(Participants) | Tirzepatide - MTD | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 195 | 205 | 400 |
| Not Hispanic or Latino | 164 | 159 | 323 |
| Unknown or Not Reported | 5 | 3 | 8 |
| Race (NIH/OMB)(Participants) | Tirzepatide - MTD | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 24 | 23 | 47 |
| Asian | 58 | 73 | 131 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 3 |
| Black or African American | 22 | 14 | 36 |
| White | 256 | 256 | 512 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Tirzepatide - MTD | Placebo | Total |
|---|---|---|---|
| Argentina | 101 | 103 | 204 |
| Brazil | 51 | 54 | 105 |
| China | 25 | 30 | 55 |
| India | 9 | 11 | 20 |
| Israel | 17 | 21 | 38 |
| Mexico | 41 | 40 | 81 |
| Russia | 13 | 8 | 21 |
| Taiwan | 24 | 32 | 56 |
| United States | 83 | 68 | 151 |
Showing the first 100 of 146 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2021 to primary completion in Jul 2024, 38 months.
Results were first posted in Aug 2025, 1 year 1 month after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 38 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide